Health ❯ Obesity

Treatment Options

Medications Pharmaceuticals Oral Medications Medication Weight Loss Drugs Clinical Trials Injectable Medications GLP-1 Medications GLP-1 Agonists Drug Efficacy GLP-1 Receptor Agonists Pharmaceutical Treatments Weight Loss Injections Pharmaceutical Innovations GLP-1 Drugs Drug Development Drug Combinations Semaglutide Bariatric Surgery Drug Therapies GLP-1 Therapies Surgical Procedures Clinical Studies Hormonal Treatments Patient Preferences Drug Mechanisms Injectable vs Oral Drugs Regulatory Issues Prescription Medications Telehealth Services Patient Access Pharmacy Services Drug Candidates Medication Risks Clinical Development Surgery vs. Medication Weight Loss Therapies Weight-Loss Drugs Compounded Medications Drug Delivery Systems Incretin Medications Weight Loss Strategies Non-Invasive Procedures Injectable vs Oral Medications Clinical Support Medical Interventions Microdosing Lifestyle Changes Medications for Obesity Gene Therapy Medication Use Patient Awareness Diabetes Management NHS Endocrinology Weight-loss Injections Patient Compliance Orforglipron GLP-1 Therapy Diet and Exercise Prescription Drugs

Lilly Will Seek FDA Approval for Retatrutide in Q1 2027 After Two More Positive Phase 3 Trials

Unclear cardiovascular signals together with unfinished manufacturing checks could shape regulators' verdict on Lilly's application.

UCL Review Finds GLP‑1 Drugs Reduce Binge Eating Symptoms

Study Finds Small Rise in Smell and Taste Diagnoses Among People on GLP‑1 Diabetes Drugs

GLP‑1 Drugs Move into the Mainstream as UK Clears Oral Wegovy and Tirzepatide Shows Bigger Weight Loss

AstraZeneca’s Oral GLP‑1 Elecoglipron Delivers Strong Phase 2 Weight and Blood‑Sugar Results

CVS Caremark Restores Zepbound and Adds Lilly’s Foundayo to Standard Formularies

Novo Nordisk Lifts 2026 Outlook as Wegovy Pill Powers Big Q1 Beat

Amazon Pharmacy Launches Same-Day Delivery for Lilly’s Foundayo Weight-Loss Pill

Novo Nordisk Invests €432 Million to Expand Athlone Plant for Oral GLP-1 Tablets

Eli Lilly Builds $1.5 Billion Stockpile of Orforglipron as FDA Decision Nears

Novo’s New GLP‑1 Pill Tests Lilly’s Lead as Investors Eye Pfizer’s Cheaper Shares

FDA Approves Wegovy Weight-Loss Pill as First Oral GLP-1 for Obesity

GLP-1 Drugs Are Changing What Households Buy, Study Finds

Pfizer Licenses Early-Stage Oral GLP-1 From YaoPharma in Up to $2 Billion Deal

Structure Therapeutics' Oral GLP-1 Posts Up to 15% Placebo-Adjusted Weight Loss as Company Prepares Phase 3

Eli Lilly Becomes First Health Care Company Valued at $1 Trillion

Pfizer Closes Metsera Buyout, Adding GLP-1 Assets in Cash-Plus-CVR Deal

Novo Nordisk Slashes Wegovy Price in India by Up to 37% to Take On Mounjaro

Pfizer Clinches $10 Billion Metsera Deal After Novo Nordisk Withdraws

Pfizer Wins Early U.S. Antitrust Clearance for Metsera Deal as Novo’s Higher Bid Pressures Timeline